Basic information
- CAS
25990-43-6- Standard SMILES
C[N+]1(C)CCCC(OC(=O)C(O)(c2ccccc2)c2ccccc2)C1- InChIKey
GKNPSSNBBWDAGH-UHFFFAOYSA-N- Molecular formula
- C21H26NO3+
- Average molar mass
- 340.4 g/mol
- Monoisotopic mass
- 340.19126869
Overview
2-hydroxy-2,2-diphenylacetic acid (1,1-dimethyl-3-piperidin-1-iumyl) ester is a diarylmethane.
Names & identifiers
- Preferred name
- Mepenzolate
- IUPAC
- (1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetate
- English name
- Mepenzolon
- Molecular formula
- C21H25NO3
- Molecular weight
- 0
Names & synonyms
mepenzolateMepenzolic acidMepenzolate ion25990-43-6Mepenzolate cationONW3LB39P7Mepenzolate bromide free baseDTXSID2046969(1,1-dimethylpiperidin-1-ium-3-yl) 2-hydroxy-2,2-diphenylacetatePiperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1,1-dimethylpiperidin-1-iumPIPERIDINIUM, 3-((HYDROXYDIPHENYLACETYL)OXY)-1,1-DIMETHYL-
Show more names
3-[(Hydroxydiphenylacetyl)oxy]-1,1-dimethylpiperidiniumPiperidinium, 3-hydroxy-1,1-dimethyl-, benzilate (ester) (8CI)Piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl- (9CI)
3-((2-hydroxy-2,2-diphenylacetyl)oxy)-1,1-dimethylpiperidin-1-iumRefChem:925490DTXCID0026969CantrilMepenzolon1-Methyl-3-piperidyl benzilate methyl bromideUNII-ONW3LB39P7racemic mepenzolate
Database identifiers
- CAS
25990-43-6
Properties
Computed structural properties
- XLogP
- 3.2
- Topological polar surface area
- 46.5 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 3
- Rotatable bonds
- 5
- Heavy atoms
- 25
- Formal charge
- 1
- Complexity
- 432
Experimental & physicochemical properties
Solubility6.27e-04 g/L
Human Drugs
Breast Feeding; Lactation; Anti-Ulcer Agents; Muscarinic Antagonists; Parasympatholytics
Pharmaceuticals
Physical DescriptionSolid
Collision Cross Section179.23 Ų [M]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
Physicochemical properties
- Boiling point
- 0.03 · bp0.03 175-176°
- FDA UNII
- 3 LB39P7 · ONW3LB39P7
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Hazard information
Other Safety InformationIMAP assessments - Piperidinium, 3-[(hydroxydiphenylacetyl)oxy]-1,1-dimethyl-: Environment tier I assessment
Toxicology
HepatotoxicityLike other anticholinergic agents, mepenzolate has not been linked to episodes of liver enzyme elevations or clinically apparent liver injury. The metabolism of mepenzolate is not well defined, but it is likely metabolized by the liver.
Drug Induced Liver Injury
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
mepenzolate
DILI Negative
Oral
DOI:10.1016/j.drudis.2019.09.022
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Chemistry & industry
Pharmacology
ATC Code
A - Alimentary tract and metabolism
QA - Alimentary tract and metabolism
PharmacodynamicsMepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ganglionic parasympathetic inhibitor.
Mechanism of ActionMepenzolate is a post-ganglionic parasympathetic inhibitor. It specifically antagonizes muscarinic receptors. This leads to decreases in gastric acid and pepsin secretion and suppression of spontaneous contractions of the colon.
FDA Pharmacological Classification
ONW3LB39P7
MEPENZOLATE
Established Pharmacologic Class [EPC] - Anticholinergic
Mechanisms of Action [MoA] - Cholinergic Antagonists
Mepenzolate is an Anticholinergic. The mechanism of action of mepenzolate is as a Cholinergic Antagonist.
Absorption, Distribution and Excretion
Between 3 and 22% of an orally administered dose is excreted in the urine over a 5-day period, with the majority of the radioactivity appearing on Day 1. The remainder appears in the next 5 days in the feces and presumably has not been absorbed.
Between 3 and 22% of an orally administered dose is excreted in the urine over a 5-day period, with the majority of the radioactivity appearing on Day 1.
Cellular LocationsMembrane
Uses & manufacturing
Use ClassificationPharmaceuticals
Applications
UsesAnticholinergic.
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…